Clinical Trial Update: An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84 [Phase 1]

View source ↗

Summary

An open-label Phase 1 study assessing the safety, immunogenicity and dose response of IC84 in Clostridioides difficile infection; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection

Drugs mentioned

• IC84

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Clostridium Difficile Infection | Phase 1 | Status: COMPLETED